Cybin (HELP) Income towards Parent Company (2020 - 2022)

Cybin's (HELP) quarterly Income towards Parent Company came in at $4.6 million in Q2 2022, up 186.82% on a QoQ basis from -$5.2 million in Q1 2021.

Cybin (HELP) Income towards Parent Company (2020 - 2022) Analysis & Trends

Cybin (HELP) has 3 years of Income towards Parent Company data on file, last reported at $4.6 million in Q2 2022.

Quarterly Income towards Parent Company changed N/A year-over-year to $4.6 million in Q2 2022, while the trailing twelve-month figure through Mar 2026 was -$0.0 (changed 0.0% YoY) and the FY2026 annual result came in at -$147.8 million, down 53.91% from the prior year.
Income towards Parent Company grew to $4.6 million in Q2 2022, from -$5.2 million in the prior quarter.
In the past five years, Income towards Parent Company ranged from a high of $144.2 million in Q2 2020 to a low of -$162.1 million in Q4 2020.
A 3-year average of -$3.7 million and a median of -$1921.8 in 2020 frame the typical range for Income towards Parent Company.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Cybin	417.29 Mn	417.29 Mn	-

Download Data